| Yuan Yang,Baohua Lu,Baolan Li,Weiying Li,Mei Jiang,Wentao Yue,Qunhui Wang,Tongmei Zhang. The expression of vascular endothelial growth factor (VEGF)/ endostatin (ES) and VEGF receptor 2 (VEGFR2)/ES is associated with NSCLC prognosis. Oncol Transl Med, 2021, 7: 149-154. |
| The expression of vascular endothelial growth factor (VEGF)/ endostatin (ES) and VEGF receptor 2 (VEGFR2)/ES is associated with NSCLC prognosis |
| Received:February 25, 2020 Revised:August 10, 2021 |
| View Full Text View/Add Comment Download reader |
| KeyWord:non-small cell lung cancer (NSCLC); angiogenesis; clinical characteristics; prognosis |
| Author Name | Affiliation | E-mail | | Yuan Yang | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | yangyuan1919@163.com | | Baohua Lu | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | | | Baolan Li | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | | | Weiying Li | Laboratory of Cell Biotechnology, Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Mei Jiang | Laboratory of Cell Biotechnology, Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Wentao Yue | Laboratory of Cell Biotechnology, Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Qunhui Wang | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | | | Tongmei Zhang | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | |
|
| Hits: 3354 |
| Download times: 3780 |
| Abstract: |
| Objective: The aim of our study was to detect the expression of angiogenesis inhibitory proteins and
angiogenesis promotive proteins in the postoperative tumor tissue of non-small cell lung cancer (NSCLC)
patients. We also investigated the relationship of protein expression with clinical characteristics and
prognosis.
Methods: We examined the expression of vascular endothelial growth factor (VEGF), VEGF receptor 2
(VEGFR2), and endostatin (ES) proteins in 255 specimens resected from NSCLC patients, using immune
histochemistry (IHC). We then evaluated the relationships between the expression of the three proteins
and clinical characteristics such as stage, histological type, differentiation, gender, tobacco use, and
age. According to the value of VEGF/ES, we divided the cohort into angiogenesis-promoting group A,
angiogenesis-inhibiting group A, and balance group A. The survival differences in the three groups were
evaluated to determine the prognostic value of VEGF/ES. Similarly, we tested the prognostic value of
VEGFR2/ES.
Results: VEGF-positive expression was observed in 93 patients (36.4%). VEGF expression was not
correlated with the clinical characteristics. VEGFR2-positive expression was observed in 103 patients
(40.4%). The expression of VEGFR2 was correlated with the clinical stage (χ2 = 21.414, P = 0.045) and
histological type (χ2 = 26.911, P = 0.008). ES-positive expression was observed in 140 patients (54.9%).
The expression of ES was correlated with the clinical stage (χ2 = 26.504, P = 0.009). When evaluating
the prognostic values of VEGF/ES and VEGFR2/ES, the prognosis of the angiogenesis balance group
was similar to that of the angiogenesis-inhibiting group. The minimum survival time was observed in the
angiogenesis-promoting group.
Conclusion: VEGF/ES and VEGFR2/ES in resected tumors have prognostic value in postoperative
NSCLC patients. The survival time of the population with predominant angiogenic factors was short. |
| Close |
|
|
|